Analyses of prognostic indices of chronic liver failure caused by hepatitis virus.

Department of Obstetrics and Gynecology, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, Guangdong Province, China.
World Journal of Gastroenterology (Impact Factor: 2.43). 06/2005; 11(18):2841-3.
Source: PubMed

ABSTRACT To analyze the related indices about the prognoses of chronic liver failure caused by hepatitis virus.
Retrospectively reviewed 320 cases of chronic liver failure caused by hepatitis viruses. An improved group and an ineffective group (IG) were made to compare and analyze their clinical manifestations, laboratory examination indices and complications. Logistic regression was also carried out.
There were significant differences (P<0.05) between the improved group and the IG upon such indices as age, bilirubin, prothrombin time, albumin, alpha fetoprotein, the size of liver and complications (P<0.05). The regression formula was as follows: P = 1/(1+e(-y)) (y = 1.7262-0.0948X(1)+2.9846X(2)+0.6992X(3)+1.6019X(4)+ 2.0398X(5)). (Note: X(1)-Prothrombin activity; X(2)-digestive tract hemorrhage; X(3)-hepatic encephalopathy; X(4)-hepatorenal syndrome; X(5)-pulmonary infection.).
Laboratory examination such as bilirubin, prothrombin time and alpha fetoprotein can be regarded as indices of the prognoses of chronic liver failure caused by hepatitis. Moreover, the regression equation can evaluate prognoses more comprehensively and direct our treatments.


Available from: Zhongjie Shi, May 30, 2015
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the present study was to establish noninvasive diagnostic models of liver fibrosis and assess their predictive accuracy (AC). A total of 349 patients with chronic hepatitis B virus infection were collected, who underwent liver biopsy and pathologic examination at Beijing Ditan Hospital affiliated to Capital Medical University. Patients were grouped according to the phase of disease: immune tolerant (n = 125) or immune reactive hepatitis B e antigen (HBeAg) positive (n = 224). Diagnostic models were based on independent markers of liver fibrosis. Receiver operating characteristic (ROC) curves were used to set cutoff values and evaluate the diagnostic value of the models. Wang I and Wang II models were constructed using independent disease markers. Wang I model cutoff values ≤1.75 and >5.84 were used to identify patients in the immune tolerance phase with or without significant fibrosis. The area under the ROC curve for this model was 0.866 (95% CI, 0.790-0.942) and the AC was 92.0%. The application of this model would enable 87 patients (69.6%) to avoid liver biopsy. Wang II model cutoff values ≤3.79 and >7.06 were used to identify immune reactive HBeAg-positive patients with or without significant fibrosis. The area under the ROC curve was 0.872 (95% CI, 0.824, 0.920) and the AC was 88.0%. The application of this model would enable 166 patients (74.1%) to avoid liver biopsy. Both Wang models enabled noninvasive liver fibrosis assessment with reliable predictive power and reproducibility for diagnosis of fibrosis in immune tolerant and immune reactive HBeAg-positive patients. With further development, these models may provide a clinical alternative to liver biopsy.
    Journal of Surgical Research 10/2013; 8(1). DOI:10.1016/j.jss.2013.10.034 · 2.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatic encephalopathy (HE) is an important neuropsychiatry complication of acute-on-chronic liver failure (ACLF). PPI therapy may increase the intestinal bacterial overgrowth and infections. The aim of this study was to assess whether PPI use in ACLF is associated with HE. A retrospective case-control study was performed. Fifty five admitted patients with hepatitis B virus (HBV)-related ACLF complicated by Stage II-IV HE developed after admission between January 2008 and December 2012 were matched (by sex, age, and MELD score) with comparable HBV-related ACLF patients (n = 110) who did not develop this complication during hospitalization. We excluded combined HE upon admission and other neurological disorders in patients with ACLF. Univariate and multivariate analyses of 30 variables (laboratory examination, predisposition, treatment, etc.) before the occurrence of HE were carried out to identify the factors predictive of HE. In univariate analysis, patients with HE in ACLF had a significantly higher rate of PPI use (89.1%) compared with non-HE (63.6%, P = 0.001). In addition, clinical and standard laboratory variables were significantly different between the two groups regarding the infection rate, hyponatremia, alpha-fetoprotein (AFP), Arginine Hydrochloride use and Lactulose use. Logistic regression analysis was used to examine the combined effects of the variables with HE as the outcome. HE in ACLF was associated with hyponatremia (odds ratio (OR) = 6. 318, 95% confidence interval (CI) = 2. 803-14.241; P = 0. 000), PPI use was independently associated with HE (OR = 4. 392, CI = 1. 604-12.031; P = 0. 004), and lactulose use was protective (OR = 0. 294, CI = 0. 136-0.675; P = 0. 003). The occurrence of HE is associated with hyponatremia and PPI use in patients with ACLF.
    Hepatitis Monthly 04/2014; 14(4):e16258. DOI:10.5812/hepatmon.16258 · 1.80 Impact Factor